Balderton Capital
Venture capital firm based in London, UK
Balderton Capital Investments
Balderton Capital has invested in these startups.
32Co
London-based healthtech startup, 32Co, raises £2.2 million in funding to expand its platform that connects general clinicians with specialists, revolutionizing healthcare collaboration and eliminating the need for travel and high costs. Read more
Sylvera
Sylvera secures $57 million in Series B funding to scale its carbon credit ratings platform and drive climate action investments, making waves in the fight against climate change. Read more
TreasurySpring
London-based fintech firm TreasurySpring raises $29M in Series B funding, led by Balderton Capital, for its first-of-its-kind investment platform that allows firms of all sizes to diversify their cash deposits and access high-quality investments while minimizing banking risks. Read more
Qargo
Qargo secures €12m in funding to revolutionize transportation management with innovative SaaS solution minimizing emissions and maximizing efficiency. Read more
Sava
Sava secures $8M in Seed funding to revolutionize health monitoring with their wearable biosensor platform, poised to transform the digital health space and improve health outcomes. Read more
Tilt
Get ready for a shopping revolution as Tilt secures $18 million to supercharge their interactive app, transforming online fashion into a vibrant, real-time experience! Read more
Convergence
Convergence scores a game-changing $12 million in Pre-Seed funding to unleash its revolutionary AI agent, Proxy, set to transform how we tackle everyday tasks! Read more
Healx
Healx secures $47 million in Series C funding to advance cutting-edge treatments for rare diseases, with renowned biotech leaders, including Stanford Medicine's Dr. Ronjon Nag, joining the board to drive innovation. Read more
Investments By Sector
Balderton Capital has invested in these sectors
| Ecommerce | 23.1% |
| Healthtech | 15.4% |
| Fintech | 15.4% |
| Greentech | 15.4% |
| Legaltech | 15.4% |
| AI | 7.7% |
| Biotech | 7.7% |
